New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
08:57 EDTHEBHemispherx to present results to date of Ampligen/FluMist trial
Hemispherx Biopharma announced that the ASM Biodefense Meeting is scheduled for January 27-29 in Washington DC. The University of Alabama and Hemispherx's poster presentation is entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" and will be provided in poster format by Dr. E. Turner Overton, an infectious disease expert at UAB, in the afternoon of January 29. Representatives of Hemispherx Biopharma and Prof. Overton, the principal researcher conducting the clinical trial at the University of Alabama at Birmingham, will describe the results to date of the Ampligen/FluMist intranasal influenza vaccine clinical trial and address questions during a media conference at the National Press Club in Washington, DC scheduled on Thursday, January 30.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
10:01 EDTHEBHemispherx says court upholds defense in case brought by Cato Capital
Hemispherx Biopharma announced that on Friday the Third Circuit Court of Appeals upheld the company's defense of a case brought by Cato Capital, one of its former investment banks, thus affirming the trial court judgment Hemispherx obtained in September 2014, when the company fully prevailed in a federal lawsuit brought against the company following trial. The appellate panel affirmed the United States District Court for the District of Delaware, which had dismissed all claims against Hemispherx and subsequently ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76.The company's President, Thomas K. Equels, stated: "We are gratified that the distinguished panel vindicated our interpretation of the contract. Our lead counsel, James J. Black, III did an outstanding job interpreting this Delaware law based agreement, and properly navigating this dispute through the courts. Now, in furtherance of our corporate policy to seek redress against plaintiffs who bring meritless claims against the company, we will pursue Cato Capital to the fullest extent of the law to collect on the award of attorney's fees and costs."
August 24, 2015
08:37 EDTHEBHemispherx enters into supply agreement with Gulf Coast Regional Blood Center
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use